Filter Results:
- Full text PDF available (117)
Publication Year
1974
2018
- This year (22)
- Last 5 years (124)
- Last 10 years (247)
Publication Type
Co-author
Journals and Conferences
Method
Learn More
- Charles Balch, Jeffrey E Gershenwald, +17 authors Vernon K. Sondak
- Journal of clinical oncology : official journal…
- 2009
PURPOSE
To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database.
METHODS
The melanoma staging… (More)
- Paul B Chapman, A. H. W. Hauschild, +25 authors Grant Mcarthur
- The New England journal of medicine
- 2011
BACKGROUND
Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E… (More)
- Charles Balch, Antonio Carlos Buzaid, +15 authors J. J. Thompson
- Journal of clinical oncology : official journal…
- 2001
PURPOSE
To revise the staging system for cutaneous melanoma under the auspices of the American Joint Committee on Cancer (AJCC).
MATERIALS AND METHODS
The prognostic factors analysis described in… (More)
- Charles Balch, S. J. Soong, +16 authors Alessandro Morabito
- Journal of clinical oncology : official journal…
- 2001
PURPOSE
The American Joint Committee on Cancer (AJCC) recently proposed major revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous melanoma. Thirteen cancer… (More)
- John Munn Kirkwood, Myla Strawderman, Marc S. Ernstoff, Thomas James Smith, Ernest C. Borden, Ronald H. Blum
- Journal of clinical oncology : official journal…
- 1996
PURPOSE
Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or… (More)
- Robbie B. Mailliard, Anna Wańkowicz-Kalińska, +6 authors Pawel Kalinski
- Cancer research
- 2004
Using the principle of functional polarization of dendritic cells (DCs), we have developed a novel protocol to generate human DCs combining the three features critical for the induction of type-1… (More)
- John Munn Kirkwood, Joseph G. Ibrahim, +7 authors Ronald H. Blum
- Journal of clinical oncology : official journal…
- 2000
PURPOSE
Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk melanoma patients demonstrated a significant relapse-free and overall survival (RFS and OS)… (More)
- Julien Fourcade, Zhaojun Sun, +6 authors Hassane M. Zarour
- The Journal of experimental medicine
- 2010
The paradoxical coexistence of spontaneous tumor antigen-specific immune responses with progressive disease in cancer patients furthers the need to dissect the molecular pathways involved in… (More)
- Antoni Ribas, Igor J. Puzanov, +33 authors Adil I Daud
- The Lancet. Oncology
- 2015
BACKGROUND
Patients with melanoma that progresses on ipilimumab and, if BRAF(V600) mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the efficacy and safety of… (More)
- Antoni Ribas, Richard Kefford, +21 authors A. H. W. Hauschild
- Journal of clinical oncology : official journal…
- 2013
PURPOSE
In phase I/II trials, the cytotoxic T lymphocyte-associated antigen-4-blocking monoclonal antibody tremelimumab induced durable responses in a subset of patients with advanced melanoma. This… (More)